J&J finally grabs Actelion's marketed meds for $30B, with R&D spinoff to come

Johnson & Johnson will pay $30 billion to gain Actelion's marketed meds, which brought in $1.8 billion in the first nine months of 2016.

It took months, but growth-starved Johnson & Johnson and longtime solo flyer Actelion finally have a deal agreement that’ll make both parties happy.

The details: The New Jersey pharma giant will fork over $30 billion—$280 per Actelion share—in cash to swallow the Swiss biotech’s portfolio of marketed meds, which includes pulmonary arterial hypertension up-and-comers Opsumit and Uptravi. Actelion brought in 1.8 billion Swiss francs (about $1.8 billion) in the first nine months of 2016, so the deal will give J&J an immediate revenue boost—one large enough to swell sales growth at least 1% beyond Wall Street’s current estimates, the company said

Meanwhile, Actelion will spin out its R&D unit into a standalone company, basing and listing the new drugmaker in Switzerland and handing J&J a hefty minority stake.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

J&J has thus scored the sort of deal that many Big Pharma companies crave these days. Major drugmakers have shown they'll pay up for a company that combines marketed meds and their instant sales boost with pipeline prospects that can deliver more revenue down the road. Pfizer paid a rich $14 billion for the cancer-focused biotech Medivation last year after a bidding war that drew in Big Pharma and Big Biotech.

In Actelion's case, Sanofi jumped into the fray in hopes of a deal, but J&J elbowed the French drugmaker aside to enter exclusive deal talks in December. Those talks yielded the combination sale-and-spinoff structure, in which Actelion's longtime CEO Jean-Paul Clozel will helm his company's pipeline efforts going forward and which gives J&J that immediate sales hike.

The pair plans to close the transaction by this year’s second quarter, and once it does, J&J expects to add 35 to 40 cents to 2017 EPS. That’ll be a welcome change, considering the disappointing sales performance and flat expansion rate some of the company’s key meds put forth in Q4.

The agreement ends several months of back-and-forth between the two drugmakers, which included J&J at one point walking away. That's when Actelion struck up talks with Sanofi. But the way Actelion chairman Jean-Pierre Garnier sees it, the relatively complex deal arrangement was worth the wait.

“When a Big Pharma buys a smaller company, very often there’s also destruction of value. ... They don’t have the same culture, they don’t have the same processes," Garnier said on a Thursday conference call. "There’s always this dark side to the transaction. Today, we have found the structure that pretty much avoids these dark sides.”

“I do believe today that R&D NewCo will be a very successful company,” Clozel—who will run the new spinoff—added on the call.

J&J, of course, will benefit from that company’s success, too. It’ll initially hold 16% of shares, and it’ll have rights to another 16% through a convertible note. J&J will also pick up an option on phase 2 hypertension prospect ACT-132577.

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.